yahoo_financeOriginal article
Celldex Phase III CSU Trials Hit Endpoints as Barzolvolimab Shows Durable Responses
Phase 3positivebarzolvolimabPositive
AI Analysis
Summary
Celldex announced that barzolvolimab met primary endpoints in Phase III CSU trials with durable responses demonstrated.
Clinical Trial Data
Phase
Phase III
Primary Endpoint
Met
Outcome Details
Phase III CSU trials hit endpoints with durable responses
Importance:7/10
Sentiment:
0.80
Phase_3positive_dataendpoint_metbarzolvolimabCSU
Related Companies
Read the original article
Published by yahoo_finance on September 22, 2026 4:02 PM